



Tamara Rordorf

Kontakt

Tamara Rordorf
Rorschacherstrasse 95
9007 St. Gallen

T +41 71 494 1977
Tamara.Rordorf@kssg.ch

Bereiche

Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie

Funktion

Leitende(r) Arzt/Ärztin

Publikationen (34)

Digklia A, Kollár A, Felber Dietrich D, Kronig M, Britschgi C, Rordorf T, Jörger M, Krasniqi F, Metaxas Y, Colombo I, Ribi K, Rothermundt C. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. *Eur J Cancer* 2023; 197:113470.

Harrington K, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, Psyrrri A, Brana I, Basté N, Neupane P, Bratland Å, Fueeder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Lin J, Gumuscu B, Swaby R, Rischin D. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. *J Clin Oncol* 2022;JCO2102508.

Rischin D, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrrri A, Brana I, Neupane P, Bratland Å, Fueeder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Hong R, Mendoza R, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. *Oral Oncol* 2022; 128:105815.

Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, Psyrrri A, Brana I, Basté N, Neupane P, Bratland Å, Fueeder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Ge J, Swaby R, Gumuscu B, Harrington K. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. *J Clin Oncol* 2022; 40:2321-2332.

Gillison M, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Weibel L, Ferris R. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. *Oncologist* 2022; 27:e194-e198.

Freiberger S, Brada M, Fritz C, Höller S, Vogetseder A, Horcic M, Bihl M, Michal M, Lanzer M, Wartenberg M, Borner U, Bode P, Broglie M, Rordorf T, Morand G, Rupp N. SalivGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. *Neoplasia* 2021; 23:473-487.

Riesterer O, Pruschy M, Bender S, Sharma A, Bogowicz M, Tanadini-Lang S, Stieb S, Bertogg K, Weber S, Ikenberg K, Huber G, Schmid S, Bredell M, Veit-Haibach P, Rordorf T, Held U, Glanzmann C, Studer G. Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study. *Radiother Oncol* 2020; 150:62-69.

Sato T, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer H, Rordorf T, Maul J, Hafner J, Navarini A, Contassot E, French L. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal *Cutibacterium acnes*. *J Clin Invest* 2020; 130:1417-1430.

Nordmann T, Messerli-Odermatt O, Meier L, Micaletto S, Coppetti T, Nägeli M, Kamarachev J, Kudura K, Freiberger S, Rordorf T, Mangana J, Braun R, Dummer R. Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2 mutated extramammary Paget's disease. *Oncotarget* 2019; 10:6647-6650.

Burtness B, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrrri A, Basté N, Neupane P, Bratland Å, Fueeder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Hong R, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng J, Jin F, Rischin D. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet* 2019; 394:1915-1928.

Gillison M, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris R. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. *Oncologist* 2018; 23:1079-1082.

Schneider P, Eshmunov D, Rordorf T, Vetter D, Veit-Haibach P, Weber A, Bauerfeind P, Samaras P, Lehmann K. FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. *BMC cancer* 2018; 18:548.

Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison M. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. *Oral Oncol* 2018; 81:45-51.

Finazzi T, Rordorf T, Ikenberg K, Huber G, Guckenberger M, Garcia Schueler H. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. *BMC cancer* 2018; 18:395.

Bredell M, Rordorf T, Kroiss S, Rücker M, Zweifel D, Rostetter C. Denosumab as a Treatment Alternative for Central Giant Cell Granuloma: A Long-Term Retrospective Cohort Study. *J Oral Maxillofac Surg* 2017; 76:775-784.

Rostetter C, Rordorf T, Essig H, Zweifel D, Schumann P, Rücker M, Bredell M. Neuer Therapieansatz mit Denosumab bei Riesenzellgranulomen. Ein Fallbeispiel. *Swiss Dent J* 2017; 127:520-521.

Ernst J, Ikenberg K, Apel B, Schumann D, Huber G, Studer G, Rordorf T, Riesterer O, Rössle M, Korol D, Bredell M. Expression of CK19 is an independent predictor of negative outcome for patients with squamous cell carcinoma of the tongue. *Oncotarget* 2016; 7:76151-76158.

Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. *BMC cancer* 2016; 16:780.

Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Iglesias Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese W, Kopit J, Shaw J, Gillison M. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med* 2016; 375:1856-1867.

Brown M, Glanzmann C, Huber G, Bredell M, Rordorf T, Studer G. IMRT/VMAT for malignancies in the head-and-neck region : Outcome in patients aged 80. *Strahlenther Onkol* 2016; 192:526-36.

Ulrich A, Weiler S, Weller M, Rordorf T, Tarnutzer A. Cetuximab induced aseptic meningitis. *J Clin Neurosci* 2015; 22:1061-3.

Scharl M, Bode B, Rushing E, Knuth A, Rordorf T. Uncommon case of brain metastasis in a patient with a history of heavy smoking. *Curr Oncol* 2014; 21:e728-31.

Rordorf T, Hassan A, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbanec D, Yildiz R, Yücel S, Zekri J, Oyan B, Swiss Group for Clinical Cancer Research (SAKK). Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup. *Breast* 2014; 23:511-25.

Studer G, Linsenmeier C, Riesterer O, Najafi Y, Brown M, Yousefi B, Bredell M, Huber G, Schmid S, Studer S, Zwahlen R, Rordorf T, Glanzmann C. Late term tolerance in head neck cancer patients irradiated in the IMRT era. *Radiat Oncol* 2013; 8:259.

Anghel R, Bachmann A, Beksac M, Brodowicz T, Finek J, Komadina R, Krzemieniecki K, Láng I, Marencak J, von Moos R, Pecherstorfer M, Rordorf T, Vrbanec D, Zielinski C. Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease. *Wien Klin Wochenschr* 2013; 125:439-47.

Bredell M, Rordorf T, Studer G. Treatment concepts of oral cancer. *SADJ* 2012; 67:574-6.

Studer G, Brown M, Bredell M, Graetz K, Huber G, Linsenmeier C, Najafi Y, Riesterer O, Rordorf T, Schmid S, Glanzmann C. Follow up after IMRT in oral cavity cancer: update. *Radiat Oncol* 2012; 7:84.

Studer G, Rordorf T, Glanzmann C. Impact of tumor volume and systemic therapy on outcome in patients undergoing IMRT for large volume head neck cancer. *Radiat Oncol* 2011; 6:120.

Padberg B, Rordorf T, Suter S, Pfeiffer D, Wild D, Schröder S. 123I-Methyljodbenzylguanidin- (MIBG-) Szintigraphie: Paradoxe Nuklidspeicherung eines onkozytären Nebennierenrindenzinoms. *Pathologie* 2007; 28:281-4.

Hofer S, Seeger H, Rordorf T, Knuth A, Janzer R. Undifferentiated sarcoma arising in the brain, 23 years after curative treatment of an ependymoma. *J Neurooncol* 2005; 72:239.

Rordorf T, Züger C, Zbinden R, von Graevenitz A, Pirovino M. *Streptobacillus moniliformis* endocarditis in an HIV-positive patient. *Infection* 2000; 28:393-4.

Yu J, Zhang Y, McIlroy J, Rordorf T, Orr G, Backer J. Regulation of the p85/p110 phosphatidylinositol 3'-kinase: stabilization and inhibition of the p110 α catalytic subunit by the p85 regulatory subunit. *Mol Cell Biol* 1998; 18:1379-87.

Holzer-Petsche U, Rordorf T. Central versus peripheral site of action of the tachykinin NK1-antagonist RP 67580 in inhibiting chemonociception. *Br J Pharmacol* 1995; 115:486-90.

Rordorf T, Van Horn D, Chen D, White M, Backer J. Regulation of phosphatidylinositol 3'-kinase by tyrosyl phosphoproteins. Full activation requires occupancy of both SH2 domains in the 85-kDa regulatory subunit. *J Biol Chem* 1995; 270:3662-6.

Projekte (1)

SAKK 11/16 – Personalisierte und zellbasierte antitumorale Impfung mit MVX-ONCO-1 bei fortgeschrittenen Plattenepithelkarzinomen des Kopf-Hals-Bereiches. Eine einarmige, offene, multizentrische Phase II Studie

Klinische Forschung - 10.07.2020 - 08.11.2023

Abgeschlossen

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch